media – Page 54 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Treatment of small cell lung cancer enters a period of accelerated breakthroughs

In the field of tumors, any breakthrough is not easy. Although humans have discovered cancer for a long time, chemotherapy has long been the core treatment method. Of course, after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. For example, after decades of silence, the treatment of small cell carcinoma seems to have ushered in a period of accelerated breakthroughs. On August 15, AstraZeneca announced that its drug durvalumab has been accepted by the FDA for the indication of limited small cell lung cancer (LS-SCLC). If approved for marketing, this will be the first immunotherapy in 40 years to show survival benefits in this field, representing an important breakthrough. For limited-stage SCLC, the current first-line treatment is still chemoradiotherapy, especially the treatment of cisplatin combined with etoposide, which occupies an absolute dominant position in treatment. Amgen has also made progress in the field ...
- Source: drugdu
- 116
- August 31, 2024
Internet healthcare is more than just selling drugs

Can the business model of Internet healthcare work without selling drugs? This may be the answer that everyone wants to know at the moment. After all, Internet healthcare is recognized as a tough nut to crack. Many entrants have fallen halfway, and some survivors are not in a good situation. Ping An Health’s latest semi-annual report finally gave a definite answer. In the first half of the year, Ping An Health’s adjusted net profit reached 89.74 million yuan, a year-on-year loss of 340 million yuan. This achievement was not easy to come by. Ten years after its establishment, Ping An Health finally achieved its first profit; if compared with JD Health and Ali Health, Ping An Health’s turnaround time is also later, but the latter’s turnaround may be more meaningful to the entire Internet healthcare. The core is that, in the eyes of the outside world, whether it is JD ...
- Source: drugdu
- 75
- August 31, 2024
Part of the Product Market Promotion Did Not Meet Expectations

Relying on the agency products, “vaccine quality leading stock” Zhifei Biological delivered a double-digit revenue and net profit in the first half of the results, bluntly said that part of the region, part of the product marketing work did not meet expectations. The evening of August 29, Chongqing Zhifei Biological Products Co., Ltd (Zhifei Biological, 300122) announced 2024 semi-annual report, operating income of 18.258 billion yuan, a year-on-year decline of 25.31%; the mother of the net profit of 2.234 billion yuan, a year-on-year decline of 47.55%; the mother of the deduction of non-net profit of 2.23 billion yuan, a year-on-year decline of 47.04%. Zhifei biological performance decline is not a surprise. This year’s quarterly report shows that its quarterly operating income of 11.396 billion yuan, up 2% year-on-year; mother net profit of 1.458 billion yuan, down 28.26% year-on-year; mother deducted net profit of 1.455 billion yuan, down 28.36% year-on-year. Combined ...
- Source: drugdu
- 79
- August 31, 2024
After being acquired by Mindray Medical, Huitai Medical’s annual report still shows high growth

Recently, Huitai Medical released its latest semi annual report, with a total revenue of 1 billion yuan in the first half of 2024, a year-on-year increase of 27.03%; Net profit of 343 million yuan, an increase of 33.09%; The non net profit attributable to the parent company was 328 million yuan, an increase of 35.2%. This is the first semi annual report of Huitai Medical after being acquired by Mindray Medical, and it still maintains a high growth trend. The combination of competitive advantages and cost-effectiveness brought by strong cooperation, and being in an important window of domestic substitution, can Huitai Medical achieve rapid development without speed limit from now on? Strong collaboration Being able to be acquired by the industry leader itself indicates that Huitai Medical is excellent enough. On January 29th, Mindray Medical announced that it had acquired a total of 14.1203 million shares of Huitai Medical held ...
- Source: drugdu
- 143
- August 30, 2024
Siemens Healthineers plans to acquire Novartis’ diagnostic business for €200 million

Recently, according to the Financial Times, Siemens Healthineers plans to acquire the diagnostic business of Advanced Accelerator Applications (AAA), a subsidiary of Novartis, for 200 million euros (approximately 1.593 billion yuan). AAA specializes in producing radioactive nuclide drugs, also known as nuclear drugs, for molecular imaging equipment PET (positron emission tomography). The transaction is expected to be completed in the fourth quarter. Expand business territory AAA was spun off from the European Organization for Nuclear Research (CERN) in 2002 and is an innovative radiopharmaceutical company focused on targeted radioligand therapy, precise radioligand imaging, and molecular imaging product development. Its main focus is on the development, production, and commercial application of Molecular Nuclear Medicine (MNM) products. On October 30, 2017, Novartis acquired the company for $3.9 billion to strengthen its radiopharmaceutical business capabilities, making AAA a subsidiary of Novartis. After years of development, AAA has built a pipeline covering various diagnostic ...
- Source: drugdu
- 95
- August 30, 2024
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m

Arcus Biosciences has announced a loan from financer Hercules Capital valued at as much as $250m, contingent on the advancement of the company’s therapeutic candidates. Arcus released the news after the markets closed yesterday (27 August), outlining an initial $50m granted at the deal’s close, with another $100m available at Arcus’s discretion. Provided Hercules Capital approves, a further $100m can be drawn. The five-year loan and four-year interest-only period may each be extended another year should Arcus initiate Phase III trials for its cancer therapies, a HIF-2α inhibitor casdatifan and the CD73 inhibitor quemlicustat, and meet regulatory milestones, respectively. The deal comes as the company continues its financial recovery. Arcus’s share price dropped from a high of $49.1 in November 2021 to $13.10 in November 2023. When the market opened today (28 August), the share price stood at $17.3; the company is valued at $1.6bn. Arcus CEO Dr. Terry Rosen ...
- Source: drugdu
- 74
- August 30, 2024
Bayer teams up with lncRNA-focused NextRNA in $547m deal

Bayer has teamed up with startup biotech NextRNA Therapeutics to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology. Under the terms of the deal, NextRNA can get up to $547m if all the milestones are reached, and the deal also included an undisclosed upfront payment. The companies will collaborate on two oncology programmes, the first involving a lncRNA-targeting small molecule in early preclinical development at NextRNA. For the second, NextRNA will pursue lncRNA targets identified by its platform, with Bayer having the option to choose one target for joint development. In 2022, Dana-Farber spinout NextRNA came out of stealth with $9.3m from a seed financing round and $46.8m from a Series A. This is the first high-profile pharma deal for the startup, which focuses on lncRNA-driven diseases. lncRNAs are RNA molecules over 200 nucleotides long that regulate gene expression without coding for proteins. They play key roles in ...
- Source: drugdu
- 85
- August 30, 2024
myTomorrows and Pancreatic Cancer Europe partner on clinical trials

The partnership will improve care for patients with pancreatic cancer myTomorrows, a global health technology company connecting patients with all possible treatment options, has announced a new partnership with Pancreatic Cancer Europe, a multi-stakeholder platform that brings together experts from all over Europe to improve care for patients with pancreatic cancer. Through the new partnership, Pancreatic Cancer Europe (PCE) will utilise myTomorrows’ database of ongoing clinical trials to equip patients, caregivers and healthcare professionals (HCPs) with up-to-date, accessible information about pre-approval treatments that may be relevant to them. The partnership with the European patient advocacy group and myTomorrows will help to expand access to all possible treatment options for patients suffering from a variety of life-threatening illnesses. For pancreatic cancer patients and HCPs, the partnership will help make the process of identifying and understanding the existing clinical trial options easier. Pancreatic cancer is the fourth leading cause of cancer deaths, ...
- Source: drugdu
- 86
- August 30, 2024
Acelyrin’s izokibep for hidradenitis suppurativa reveals positive results

Acelyrin has shared positive results from a late-stage study of its IL-17A inhibitor izokibep in hidradenitis suppurativa (HS), but has said it will not be moving forward with the asset in this indication. Estimated to affect about 1% of the population in most studied countries, HS is a chronic inflammatory skin condition that causes painful nodules and abscesses. In the phase 3 trial, izokibep demonstrated statistically significant responses across multiple efficacy endpoints at week 12, with 33% of patients being treated with izokibep 160mg weekly achieving at least a 75% reduction in total abscess and inflammatory nodule count (HiSCR75) compared to 21% of those receiving placebo. Results also showed that 25% and 22% of izokibep-treated patients achieved HiSCR90 and HiSCR100, respectively, compared to 9% and 8% in the placebo cohort. The announcement comes shortly after the drug demonstrated promising results in a phase 2b/3 study for psoriatic arthritis (PsA), a ...
- Source: drugdu
- 66
- August 30, 2024
【EXPERT Q&A】What are Radioactive Drug Conjugates (RDCs)?

Drugdu.com expert’s response: Radioactive Drug Conjugates (RDCs) represent a novel class of therapeutic agents that combine the strengths of precise targeting and potent killing capabilities. By linking radioactive nuclides to ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators, RDCs achieve precise localization and effective eradication of target cells. Below, I will elaborate on RDCs from four aspects: definition and structure, advantages and applications, classification, as well as challenges and prospects. I. Definition and Structure Definition: RDCs are drug formulations that integrate radioactive nuclides with targeting molecules (ligands) through linker arms (connectors), aimed at delivering precise strikes against tumor or other disease targets. Structure: RDC drugs consist primarily of targeting ligands, linker arms, chelators, and nuclide conjugates. The targeting ligands recognize and bind to specific target cells or tissues; linker arms connect the targeting ligands to the radioactive nuclides; chelators stabilize the radioactive nuclides, preventing their premature ...
- Source: drugdu
- 69
- August 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.